FDA — authorised 7 September 2022
- Application: BLA761127
- Marketing authorisation holder: REVANCE THERAPEUTICS, INC.
- Local brand name: DAXXIFY
- Indication: INJECTABLE — INTRAMUSCULAR, SUBCUTANEOUS
- Status: approved
🇺🇸 DAXXIFY in United States
FDA authorised DAXXIFY on 7 September 2022
Marketing authorisations
FDA
- Status: approved
DAXXIFY in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is DAXXIFY approved in United States?
Yes. FDA authorised it on 7 September 2022; FDA has authorised it.
Who is the marketing authorisation holder for DAXXIFY in United States?
REVANCE THERAPEUTICS, INC. holds the US marketing authorisation.